Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATF2
REST API REST API
Homo sapiens
ATF2 is differentially expressed in 292 experiments: 132 organism parts: testis, bone marrow, ... (130 more);, 209 disease states: normal, control, ... (207 more);, 85 cell types 368 cell lines 39 compound treatments and 73 other conditions.
Synonyms CREB2, CRE-BP1, HB16, TREB7
Orthologs atf2l (Danio rerio)   Atf2 (Mus musculus)   ATF2 (Bos taurus)   ATF2_CHICK (Gallus gallus)   Atf2 (Rattus norvegicus)   atf2 (Xenopus laevis)   A7WX99_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, DNA binding, protein binding, regulation of transcription, DNA-dependent, intracellular, innate immune response, transcription, DNA-dependent, metal ion binding, nucleic acid binding, stress-activated MAPK cascade, membrane fraction, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, chromatin binding, nucleoplasm, zinc ion binding, outflow tract morphogenesis, toll-like receptor 4 signaling pathway, adipose tissue development, toll-like receptor signaling pathway, fat cell differentiation, toll-like receptor 3 signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, regulation of sequence-specific DNA binding transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, toll-like receptor 1 signaling pathway, positive regulation of transforming growth factor beta2 production
InterPro Term bZIP_1, bZIP_2, Znf_C2H2, TF_bZIP, TF_cAMP-dep
UniProt Accession Q96JT8, Q3B7B7, Q8TAR1, C9JCI8, A4D7V1, A4D7U5, B3KY57, P15336, B8ZZU6, E9PBF9, E9PEK8, F2Z2K2, F5H629
Search EB-eye ENSG00000115966
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-TABM-125, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
Jurkat
2
E-GEOD-1880, E-MEXP-2197
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
362 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (41 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-6740, E-AFMX-5
fibroblast
2
E-GEOD-3920, E-GEOD-26672
immortalised T lymphocytes
1
E-GEOD-13909
adipose tissue-derived stem cell
1
E-MEXP-872
hematopoietic stem cell
1
E-MEXP-872
interstitial stromal cells
1
E-GEOD-20758
79 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-12254, E-GEOD-16363, E-GEOD-20168, ... (68 experiments)

Factor Value U/D Experiments
myeloma
2
E-MTAB-37, E-MTAB-372
prostate carcinoma
2
E-MTAB-37, E-MEXP-2034
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
colon carcinoma
2
E-MTAB-62, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
203 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (21 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-20719, E-MEXP-1958, E-GEOD-412, E-GEOD-2803, ... (7 experiments)
ponasterone A
1
E-GEOD-3113
TTA
1
E-MEXP-2590
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
sapphyrin PCI-2051
1
E-GEOD-6400
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-21589, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, E-TABM-321, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (38 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Organism
studied in E-GEOD-2634, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Processing time: 0.489 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM